Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Reclast

Zoledronic Acid

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Reclast:

 BioPortfolio Logo
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing 1st June, 2009 Novartis Pharmaceuticals Corporation
- Single infusion of Reclast increases bone mass for two years in postmenopausal women with osteopenia, a condition that can lead to osteoporosis(1) - Approximately 22 million women in US have
ADA Informs Patients About Osteoporosis Medications and Oral Health 9th March, 2009 American Dental Association
ADA creates brochures with National Osteoporosis Foundation CHICAGO, March 9 /PRNewswire-USNewswire/ -- Dental patients who have been alarmed or confused by recent news reports about how osteoporosis
Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports 11th February, 2009 Novartis Pharmaceuticals Corporation
- Adding Zometa to post-surgery hormone therapy reduced risk of breast cancer return or death by 36% more than hormone therapy alone - First Phase III data to substantiate anticancer effect of Zometa
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture 5th June, 2008 Novartis
EAST HANOVER, N.J., June 5 /PRNewswire/ -- The US Food and Drug Administration (FDA) has broadened the US indication for once-yearly Reclast(R) (zoledronic acid) Injection to include the
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 31st May, 2008 Novartis
EAST HANOVER, N.J., May 31 /PRNewswire/ -- New data presented today showed that Zometa(R) (zoledronic acid) offered a significant anticancer benefit for premenopausal women with hormone-sensitive,

This page has been viewed 26 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Reclast across BioPortfolio, or for Reclast Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.